Menu
Search
|

Menu

Close
X

Cellectis SA CLLS.OQ (NASDAQ Stock Exchange Global Market)

30.83 USD
+0.00 (+0.00%)
As of Jun 20
chart
Previous Close 30.83
Open --
Volume 4,900
3m Avg Volume 83,845
Today’s High --
Today’s Low --
52 Week High 38.85
52 Week Low 21.31
Shares Outstanding (mil) 35.42
Market Capitalization (mil) 1,013.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.71 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
8
FY17
42
FY16
69
FY15
74
EPS (USD)
FY18
-0.706
FY17
-3.653
FY16
-2.305
FY15
-1.079
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
20.98
5.71
Price to Book (MRQ)
vs sector
3.73
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
0.02
16.46
LT Debt to Equity (MRQ)
vs sector
0.01
12.19
Return on Investment (TTM)
vs sector
-27.62
14.38
Return on Equity (TTM)
vs sector
-27.69
16.08

EXECUTIVE LEADERSHIP

Andre Choulika
Chairman of the Board, Chief Executive Officer, Since 2000
Salary: €309,200.00
Bonus: €19,200.00
Thierry Moulin
Chief Financial Officer, Since 2014
Salary: --
Bonus: --
Elsy Boglioli
Chief Operating Officer, Executive Vice President - Strategy and Corporate Development, Since 2018
Salary: --
Bonus: --
David Sourdive
Executive Vice President-Corporate Development, Director, Since 2008
Salary: €214,400.00
Bonus: €34,400.00
Stephane Depil
Senior Vice President - Research and Development and Chief Medical Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

8 rue de la Croix-Jarry
PARIS     75013

Phone: +331.81691600

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

SPONSORED STORIES